Generic placeholder image

Current Aging Science

Author(s): Dorsaf Saadouli*, Khaoula Ben Mansour, Salem Yahyaoui, Naouel El Afrit, Amel Lahmar and Ali El Afrit

DOI: 10.2174/1874609813666200128110820

DownloadDownload PDF Flyer Cite As
Ocular Manifestations in Late Onset Behçet’s Disease

Page: [56 - 61] Pages: 6

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Behçet’s disease is frequent in Tunisia and potentially serious, which can endanger both the vital and visual prognosis. Late occurrence of the disease is uncommon and less frequently investigated.

Aims: The aim of this study was to analyse the demographic characteristics and ocular manifestations of patients with late-onset Behçet disease in Tunisia, North Africa.

Methods: A retrospective study was performed on 38 eyes of 21 oculo-Behçet patients over a seven- year period.

Results: The mean age of our patients was 54.81 years. The sex ratio M/F was 2.5. The period between the onset of the first symptom and diagnosis of Behçet’s disease varied from 3 days to 2 years. The primary complaint was a decrease in visual acuity, reported in 8 patients. Ocular involvement revealed Behçet’s disease in 2 patients, bilateral in 17 patients, and active in 31 eyes. The ocular manifestations in late-onset Behçet’s disease were dominated by uveal involvement (30 eyes). The most frequent form of uveitis was panuveitis noted in 13 eyes. Ocular complications were dominated by macular involvement in 8 patients (14 eyes). Blindness was noted in 4 eyes of 4 patients (10.5%). Topical corticosteroids were used in 30 eyes. Three patients were treated only with oral corticosteroid and 9 patients with a combination of oral corticosteroid and immunosuppressive agents.

Conclusion: Since the course of the ocular involvement in late-onset Behçet’s disease is regarded to be relatively mild, it is noteworthy that our study revealed that blindness was noted in 10,5% and posterior uveitis and panuveitis were the most common uveal lesion.

Keywords: Behçet’s disease, late onset, aging, ocular involvement, uveitis, blindness.

Graphical Abstract

[1]
Khairallah M, Ben Yahia S, Kahloun R, Khairallah-Ksiaa I, Messaoud R. Eil et maladie de behçet. J Français d’ Ophtalmologie 2012; 35(10): 826-37.
[http://dx.doi.org/10.1016/j.jfo.2012.06.016]
[2]
Accorinti M, Pesci FR, Pirraglia MP, Abicca I, Pivetti-Pezzi P. Ocular behçet’s disease: Changing patterns over time, complications and long-term visual prognosis. Ocul Immunol Inflamm 2017; 25(1): 29-36.
[http://dx.doi.org/10.3109/09273948.2015.1094095] [PMID: 26727030]
[3]
Chung Y-R, Lee E-S, Kim MH, Lew HM, Song JH. Changes in ocular manifestations of behçet disease in korean patients over time: A single-center experience in the 1990s and 2000s. Ocular Immunology and Inflammation Mars 2015; 23(2): 157-61.
[4]
Sungur G, Hazirolan D, Hekimoglu E, Kasim R, Duman S. Late-onset Behçet’s disease: Demographic, clinical, and ocular features. Graefes Arch Clin Exp Ophthalmol Sept 2010; 248(9): 1325-30.
[http://dx.doi.org/10.1007/s00417-010-1399-5]
[5]
Hamzaoui A, Jaziri F, Salem TB, Ghorbel FSIB, Lamloum M, Khanfir MS, et al. Comparison of clinical features of Behcet disease according to age in a Tunisian cohort. Acta Medica Iranica 2014; 52(): 748-51.
[6]
Alpsoy E, Donmez L, Onder M, et al. Clinical features and natural course of Behçet’s disease in 661 cases: A multicentre study. Br J Dermatol nov 2007; 157(5): 901-6.
[http://dx.doi.org/10.1111/j.1365-2133.2007.08116.x]
[7]
Ghembaza MEA, Lounici A. Relationship between age at onset and clinical characteristics of Behçet’s disease 2018.http://acta-apa.mf.uni-lj.si/journals/acta-dermatovenerol-apa/papers/10.15570/actaapa.2018.37/actaapa.2018.37.pdf
[http://dx.doi.org/10.15570/actaapa.2018.37]
[8]
Trusko B, Thorne J, Jabs D, Lakhdar H. The standardization of uveitis nomenclature (Sun) project: Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med 2013; 52(3): 259-65.
[9]
El Fajri S, Benchikhi H, Jarmouni R, Lakhdar H. Comparison of diagnostic criteria in Moroccan patients with Behçets disease. Ann Dermatol Venereol 2000; 127: 1068-72.
[10]
Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005; 50(4): 297-350.
[http://dx.doi.org/10.1016/j.survophthal.2005.04.009] [PMID: 15967189]
[11]
Saricaoglu H, Karadogan SK, Bayazit N, Yucel A, Dilek K, Tunali S. Clinical features of late-onset Behçet’s disease: Report of nine cases: Late onset Behçet’s disease. International J Dermatol 2006; 45(11): 1284-7.
[12]
Citirik M, Berker N, Songur MS, Ozkan SS, Zilelioglu O. Ocular manifestations of late-onset behçet disease. Ophthalmologica 2011; 225(1): 21-6.
[http://dx.doi.org/10.1159/000318601]
[13]
Hazirolan D, Sungur G, Duman S. Demographic, clinical, and ocular features in patients with late-onset behçet disease. Ocular Immunology and Inflammation avr 2012; 20(2): 119-24.
[http://dx.doi.org/10.3109/09273948.2012.655882]
[14]
Ziadé N, Awada H. Late onset Behçets disease. Joint Bone Spine 2006; 73(5): 567-9.
[http://dx.doi.org/10.1016/j.jbspin.2006.06.002]
[15]
Tsai J, Chen G-S, Lu Y-W, Wu C-S, Lan C-CE. Late-onset Behçets disease does not correlate with indolent clinical course: report of seven Taiwanese patients. J Eur Acad Dermatol Venereol 2008; 22(5): 596-600.
[http://dx.doi.org/10.1111/j.1468-3083.2007.02556.x] [PMID: 18266686]
[16]
Bardak Y. Effects of age and sex on Behçet’s disease. J Rheumatol 1999; 26(4): 1008-9.
[PMID: 10229439]
[17]
Yazici H, Tuzun Y, Pazarli H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behcet’s syndrome. Annals of the Rheumatic Disease 1984; 43(6): 783-9.
[http://dx.doi.org/10.1136/ard.43.6.783]
[18]
Desbois A-C, Terrada C, Cacoub P, Bodaghi B, Saadoun D. Les manifestations oculaires de la maladie de Behçet. La Revue de Médecine 2018; 39(9): 738-45.
[http://dx.doi.org/10.1016/j.revmed.2018.02.022]
[19]
Ryu HJ, Seo MR, Choi HJ, Baek HJ. Clinical phenotypes of Korean patients with Behcet disease according to gender, age at onset, and HLA-B51. Korean J Intern Med 2018; 33(5): 1025-31.
[20]
Ishido T, Horita N, Takeuchi M, et al. Clinical manifestations of Behçet’s disease depending on sex and age: Results from Japanese nationwide registration. Rheumatology 2017; 56(11): 1918-27.
[21]
Melikoğlu MA, Melikoğlu M. The influence of age on behcet’s disease activity. Eurasian J Med 2008; 40(2): 68-71.
[PMID: 25610030]
[22]
Mendes D, Correia M, Barbedo M, et al. Behçet’s disease: A contemporary review. J Autoimmun 2009; 32(3-4): 178-88.
[23]
Arevalo JF, Lasave AF, Al Jindan MY, et al. Uveitis in Behçet disease in a tertiary center over 25 years: The KKESH uveitis survey study group. Am J Ophthalmol 2015; 159(1): 177-84. e1, 2.
[http://dx.doi.org/10.1016/j.ajo.2014.10.013] [PMID: 25448998]
[24]
Demiroğlu H, Barişta İ, Dündar S. Risk factor assessment and prognosis of eye involvement in behçet’s disease in turkey. Ophthalmology avr 1997; 104(4): 701-5.
[http://dx.doi.org/10.1016/S0161-6420(97)30249-8]
[25]
Ambresin A, Tran T, Spertini F, Herbort C. Behçet’s disease in Western Switzerland: Epidemiology and analysis of ocular involvement. Ocul Immunol Inflamm 2002; 10(1): 53-63.
[http://dx.doi.org/10.1076/ocii.10.1.53.10326] [PMID: 12461704]
[26]
Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A. Clinical features of chinese patients with Behçet’s disease. Ophthalmology 2008; 115(2): 312-318.e4.
[http://dx.doi.org/10.1016/j.ophtha.2007.04.056] [PMID: 17692378]
[27]
Khairallah M, Attia S, Yahia SB, et al. Pattern of uveitis in Behçet’s disease in a referral center in Tunisia, North Africa. Int Ophthalmol juin 2009; 29(3): 135-41.
[28]
Benchekroun O, Lahbil D, Lamari H, et al. La maculopathie dans la maladie de Behçet. Journal Français d’Ophtalmologie févr 2004; 27(2): 154-9.
[http://dx.doi.org/10.1016/S0181-5512(04)96110-4]
[29]
Kahloun R, Ben Yahia S, Mbarek S, Attia S, Zaouali S, Khairallah M. Macular involvement in patients with Behçet’s uveitis. J Ophthal Inflamm Infect sept 2012; 2(3): 121-4.
[30]
B’chir Hamzaoui S, Harmel A, Bouslama K, et al. La maladie de Behçet en Tunisie. La Revue de Médecine Interne 2006; 27(10): 742-50.
[31]
Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis 2018; 77(6): 808-18.
[32]
Foster S, Zakka FR, Chang PY, Giuliari GP. Current trends in the management of ocular symptoms in Adamantiades-Behçet’s disease. OPTH oct 2009; 567.
[33]
Otmani F. Maladie de Behçet : Les nouvelles thérapeutiques. La Revue de Médecine Interne déc 2009; 30: S243-52.
[http://dx.doi.org/10.1016/j.revmed.2009.09.023]
[34]
Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: An open-label trial. Arthritis Rheum août 2005; 52(8): 2478-84.
[35]
Gul A. Standard and novel therapeutic approaches to behçets disease. Drugs 2013; 67(14): 2013-2.
[36]
Razzak A, Kassimi A, Mchachi A, et al. OEil et maladie de behçet: Profil épidémiologique, clinique, thérapeutique et évolutif. Pan Afr Med J 2019; 33.
[http://dx.doi.org/10.11604/pamj.2019.33.116.17111]